ReviewCurrent oncology (Toronto, Ont.)2022
Linking Intermediate to Final "Real-World" Outcomes: Is Financial Toxicity a Reliable Predictor of Poorer Outcomes in Cancer?
Review in Current oncology (Toronto, Ont.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 16 citations in OpenAlex.
- Financial toxicity among breast cancer survivors receiving care during the pandemic.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Impacts of Financial Toxicity on Patients Receiving Dialysis: An Exploratory Qualitative Study.Kidney360 · 2026Article
- The role of financial distress as a patient-relevant endpoint in early benefit assessments for oncology drugs: a mixed-methods document analysis.International journal of technology assessment in health care · 2026Article
- Financial toxicity on treatment outcomes in head & neck cancer patients undergoing radiation therapy.Radiation oncology (London, England) · 2025Article
- Impact of age and treatment-related adverse events on financial toxicity among patients with breast cancer: a systematic review.Journal of cancer survivorship : research and practice · 2025Article
- Hidden costs and unmet supportive care needs among individuals with experience of breast cancer and their carers in the United Kingdom.BJC reports · 2025Article
- Financial toxicity in patients with glioblastoma.Journal of neuro-oncology · 2025Article
- Societal Perspectives and Real-World Cost-Effectiveness: Expanding the Scope of Health Economics Inquiry.Current oncology (Toronto, Ont.) · 2022Article
- Longitudinal Prevalence of Financial Worry in a Cohort of Patients with Advanced Colorectal Cancer: A Secondary Observational Cohort Study.Cancer control : journal of the Moffitt Cancer CenterObservational
- Financial Hardship and Unhealthy Lifestyles: Perspectives and Solutions From Breast Cancer Survivors and Their Care Teams.Cancer control : journal of the Moffitt Cancer CenterArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Traditionally, economic evaluations are based on clinical trials with well-defined patient populations that exclude many patient types. By contrast, studies that incorporate general patient populations end up including those in lower income categories, some of whom have significant financial burdens (often described as financial toxicity) related to their care. Consideration of these patient burdens when examining the incremental cost-effectiveness of newer treatments from a clinical trial perspective can result in differing conclusions regarding cost-effectiveness. The challenge is to reliably assess the link between financial toxicity, quality of life and potential decisions to forego or delay care. It is also well-documented that these financial effects are not evenly distributed across populations, with those with low income and of black or Latino decent being most affected. There is a paucity of literature in this space, but some of the early work has suggested that for lung, breast, colorectal and ovarian cancers there are poorer quality-of-life scores and/or shorter overall survival for those experiencing financial toxicity. Hence, we may see both a lower quality of life and a shorter duration of life for these populations. If this is the case, additional considerations include: are the benefits of newer, more-expensive treatment strategies muted by the lack of adherence to these newer treatments due to financial concerns, and, if true, can these effects be effectively quantified as "real-world" outcomes? This rapid review examines these possibilities and the steps that may be required to examine this reliably.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.